ArticleBreast cancer (Tokyo, Japan)2025

Reevaluating HER2-null breast cancer using an enhanced HER2 immunohistochemistry protocol.

Takeshi Ushigusa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.